Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Common genetic variants reported to be associated with BNP levels were not associated with a relevant risk of heart failure in our population-based cohort.
|
23315043 |
2013 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The comparison of prognosis⁻predictivity of a single measurement of plasma NT-pro BNP in different follow-up periods in acute HF patients has been less studied.
|
30871208 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
TC could improve 6MWD, Qol and LVEF in patients with HF and may reduce BNP and HR.
|
29375390 |
2017 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Brain natriuretic peptide (BNP) gene expression accompanies cardiac hypertrophy and heart failure.
|
11230322 |
2001 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF.
|
29912321 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration.
|
29428199 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We found that thrombin-induced COX-2 expression, PGE2 release and cardiomyocyte hypertrophy markers (increase in ANF/BNP, α-actin expression and cell surface area) was attenuated by pretreatment with CORM-2 which was partially reversed by hemoglobin (Hb) or ZnPP (an inhibitor of HO-1 activity), suggesting that HO-1/CO system may be of clinical importance to ameliorate heart failure through inhibition of inflammatory responses.
|
26385185 |
2015 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The measurements of plasma natriuretic peptides (NT-proBNP, proBNP and BNP) are used to diagnose heart failure but these are expensive to produce.
|
24101238 |
2014 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated serum levels of UCN1, ADM, and pro BNP in 86 consecutive patients with systolic HF [ejection fraction (EF) ≤45%] and 85 healthy controls.
|
25868038 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The developed LFIA for BNP could rapidly rule out HF with the naked eye, offering tremendous potential for POC test and personalized medicine.
|
28670119 |
2017 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure.
|
30867376 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) trial randomized patients with HFpEF and either prior hospitalization for HF or elevated natriuretic peptide levels (B-type NP [BNP] ≥100 pg/ml or N-terminal proBNP ≥360 pg/ml) to spironolactone or placebo.
|
28359411 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functionally, knockdown of BRD4 greatly downregulated the NPPA and NPPB in vivo and in vitro, improved the hemodynamic and biometric parameters in rat with heart failure, as well as decreased the apoptosis occurrence.
|
29352508 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac biomarkers troponin and brain natriuretic peptide/N-terminal proBNP (BNP/NT-proBNP) have been extensively studied in heart failure and acute coronary syndromes.
|
30701097 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Other cardiovascular complications seen in GBS patients were Increased pro-BNP(26.04%), raised troponin T levels(3.12%), acute coronary syndrome(2.08%), heart failure(2.08%) and abnormal 2D echo findings(8.33%).
|
31504947 |
2020 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
BNP may thus contribute to adverse myocardial remodelling in heart failure.
|
19808301 |
2008 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.
|
30912456 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The study included 46 patients with HF and implanted CRT-D. Levels of NT-pro BNP and cTnThs were assessed during a 12 month follow up.
|
31223080 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
|
29314505 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Baseline rSO2 was lower in patients with heart failure (45.2±8.3 % vs. 54.1±7.8 %, p=0.006) and was significantly linked to higher red cell distribution width (RDW) (r=-0.53, p?0.001) and higher BNP level (r=-0.45, p=0.01).
|
31177793 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical trials have documented the benefits and risks of the use of synthetic ANP (Anaritide) and BNP (Nesiritide) for treating heart failure, renal failure, and hypertension.
|
20433683 |
2011 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recommended cutoffs for BNP and NT-proBNP for ruling in and out HF were used for assessing diagnostic concordance and correlation.
|
30111510 |
2018 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Accompanying these effects, tadalafil treatment normalized BNP mRNA and prevented development of subjective signs of HF.
|
31043634 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
With the exception of transferred HF patients (n = 22), logistic regression analysis that incorporated the CONUT score and the log BNP, showed that a higher CONUT score (P = 0.019) and higher log BNP (P = 0.009) were predictors of in-hospital death, and the median duration of hospital stay was 20 days.Our results demonstrate the usefulness of CONUT scores as predictors of short-term prognosis in hospitalized HF patients.
|
29479009 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Baseline BNP; subsequent hospitalization for heart failure or death.
|
28768311 |
2017 |